Medical Practice Valuation Multiples: A 2026 Deep Dive

Medical practices sold on BizBuySell between 2021 and 2025 traded at a median earnings multiple of 2.05x, with the upper quartile reaching 2.94x. That Main Street figure sits at the bottom of a wide spectrum: medical practice valuation multiples in 2026 stretch from roughly 2x seller's discretionary earnings for a solo private practice on the open marketplace to 20x EBITDA for an ophthalmology platform acquired by private equity. The 10-turn gap reflects scale, specialty, payer mix, and buyer type, not market irrationality. This guide breaks down what each band of buyers is paying right now, what moves a practice from one band to the next, and where the hard data ends and the negotiation begins.

How to Value a Medical Practice: Three Valuation Approaches

Three valuation approaches dominate medical practice transactions, and which one applies depends almost entirely on the size of the practice and the universe of buyers.

For solo and small group practices under roughly $5M in revenue, the primary valuation method is the seller's discretionary earnings (SDE) multiple. SDE rebuilds the owner's true economic benefit by adding back salary, perquisites, one-time items, and any non-arm's-length expenses. BizBuySell's marketplace data shows medical practices selling at 1.46x to 2.94x SDE, with a median of 2.05x. These are typically buyer-operators: another physician acquiring a private practice, a small group rolling up locally, or a regional consolidator picking up a tuck-in.

For larger practices, multi-provider groups, and anything attracting institutional capital, buyers underwrite on EBITDA multiples. EBITDA strips out the owner's compensation in favor of a market-rate physician comp normalization, which produces a number a financial buyer can model against debt service and required returns. Flychain's 2026 data and lower-middle-market broker surveys put most independent medical practices at 3x-6x EBITDA. Platforms with scale, specialty premium, and ancillary revenue push significantly higher, as the specialty section below details.

The revenue multiple is a sanity check, not a primary basis for offer. BizBuySell's data shows revenue multiples between 0.42x and 0.91x (median 0.62x) for sold practices, and Sofer Advisors pegs the 2025-2026 range at 0.5x to 1.0x for smaller offices. Revenue multiples are useful for fast comparison across deals but miss the variation in profitability that earnings multiples capture.

Source: BizBuySell, FOCUS Investment Banking, Sofer Advisors

These three valuation approaches converge in a properly built quality-of-earnings (QoE) report, which is now standard in any institutional medical practice transaction. The QoE reconstructs normalized EBITDA across 12-36 months, identifies one-time items, and produces the number both sides argue over at the negotiating table. Proper normalization can swing enterprise value by $1M or more on a mid-sized practice, which is why the work is worth doing before going to market rather than during diligence. For owners considering a broader transition, our guide on selling a medical practice covers the process beyond the valuation work itself.

What Multiples for Medical Practices Look Like in 2026

Medical practice valuation multiples in 2026 are best understood as three different markets stacked on top of each other, each with its own buyer universe and pricing logic.

Main Street marketplace (sub-$2M enterprise value). BizBuySell's five-year dataset (2021-2025) puts the median earnings multiple at 2.05x and the median revenue multiple at 0.62x. The most recent two years have run hotter than the historical average: 2024 averaged 2.37x and 2025 climbed to 2.58x. Median sale price reached $485,000 in 2025 on median revenue of $790,052 and median owner earnings of $227,196 (a 28.8% margin). The five-year trajectory is the most interesting data point: median sale price grew 55% from $347,500 in 2021 to roughly $537,000 in 2025, roughly twice the rate of the overall business-for-sale market.

Lower middle market ($5M-$50M enterprise value). IBBA's Q4 2024 Market Pulse pegged the average valuation in this band at 6.0x EBITDA, on par with the late-2021 peak. This is the band where the buyer universe splits: at the lower end, regional consolidators and family offices compete with strategic acquirers; at the upper end, private equity platforms start writing the checks. Independent multi-provider groups in this range typically sell at 5x-8x EBITDA, with the spread driven by specialty mix and growth profile.

Private equity platform tier. FOCUS Investment Banking's 2026 physician practice M&A data reports the median EV/EBITDA multiple across the broader healthcare services sector at 11.5x in 2025, down from 14.5x in 2024 as higher interest rates and tighter buyer selectivity pressured valuations. Specialty-specific platform multiples remained robust, with ophthalmology, cardiology, and gastroenterology platforms still trading at low- to mid-teens multiples even as the broader index compressed.

Source: BizBuySell, IBBA Market Pulse Q4 2024, FOCUS Investment Banking 2026

Activity volume supports the multiples. PitchBook's Q4 2025 healthcare services report counted 747 transactions in 2025, up 9.6% year-over-year, with physician practice management exits jumping 57.1%. Private equity completed 79 physician practice deals in Q1 2025 alone, concentrated in dermatology, cardiology, orthopedics, and behavioral health (Sofer Advisors). The IBBA's Q4 2025 survey found that 72% of advisors expect 2026 market conditions to match (23%) or exceed (49%) the 2021 peak. Owners weighing whether to enter this market can start with a complimentary consultation to test where a specific practice would fall in the 2026 buyer universe before committing to a process.

Frequently Asked Questions

What is the typical valuation multiple for a medical practice in 2026?

There is no single typical multiple because medical practices trade in two distinct markets. Main Street practices sold through marketplaces averaged 2.05x SDE between 2021 and 2025 per BizBuySell, while institutional buyers acquire multi-provider platforms at 8x-20x EBITDA depending on specialty. The middle band of lower-middle-market independent groups typically transacts at 5x-8x EBITDA, on par with the late-2021 peak per IBBA Q4 2024 data.

How do EBITDA multiples differ from revenue multiples for medical practices?

EBITDA multiples measure earnings power and account for normalized physician compensation; revenue multiples measure top-line scale only and ignore profitability. BizBuySell data shows that medical practices selling at a 2.05x earnings median trade at roughly 0.62x revenue, so the implied earnings-to-revenue conversion runs about 30%. Buyers price on EBITDA whenever the deal is large enough to attract institutional capital; revenue is a benchmarking check, not a basis for the actual offer.

What is the difference between platform and add-on valuations in medical practice M&A?

A platform acquisition is private equity's first investment in a specialty, so the firm pays a premium for infrastructure, leadership, and scalability, typically 10x-20x EBITDA depending on the specialty. Add-on acquisitions are smaller practices folded into an existing platform; they trade 3-5 turns lower (commonly 4x-10x) because the platform supplies the infrastructure. The arbitrage between those two prices is the core of the PE roll-up model in physician practice consolidation.

How does practice size influence EBITDA multiples?

Scale is the single largest mechanical driver of the multiple. FOCUS Investment Banking's 2026 data shows practices above $5M EBITDA command 2-4 turns higher multiples than sub-$1M practices: roughly 11x-13x at platform scale versus 5x-7x for smaller add-on candidates. The premium reflects lower execution risk, better management depth, more durable referral patterns, and the ability to absorb the diligence costs that crush smaller deals.

How Specialty Affects Practice Worth

Specialty mix is the second-largest driver of medical practice valuation multiples after scale, and the spread between specialties is wider than most owners assume. Sofer Advisors estimates surgical specialties command roughly a 26% premium over primary care on valuation multiples; FOCUS Investment Banking's specialty-level data confirms the pattern at the platform tier.

Ophthalmology continues to trade at the highest multiples in healthcare services, with platform acquisitions valued at 12x-20x EBITDA and add-ons at 7x-11x. Retina-focused platforms in particular have set the ceiling, with Cencora's Retina Consultants of America transaction serving as the reference point for premium pricing. The drivers are scarcity of remaining independent groups, procedural margins, and the natural ancillary stack of imaging, ASCs, and intravitreal injections.

Cardiology platforms trade at 12x-15x EBITDA, with add-ons at 8x-12x. Strong procedural margins and a relatively small population of independent groups still available for consolidation keep the bid competitive.

Gastroenterology platforms hit roughly 10x-14x and add-ons 6x-9x. The category benefits from a high-margin ancillary in ambulatory endoscopy centers, which buyers underwrite as a separate profit pool inside the deal.

Primary care platforms top out at 8x-12x EBITDA, while add-ons drop to 3x-6x. Practices demonstrating value-based care and capitation success can push platform multiples into the low teens, because those models defend against pure fee-for-service margin compression.

Dermatology, orthopedics, and behavioral health were the most active PE targets in Q1 2025 per Sofer Advisors, with platform multiples typically landing in the 9x-13x range.

The headline takeaway is that specialty sets the multiple ceiling; scale, payer mix, and ancillaries determine where within that range a specific practice lands. An ophthalmology practice without scale or owned ASC infrastructure will not get to 18x just because the specialty supports it; a primary care group with strong commercial payer mix and embedded ancillaries can outperform its specialty's median.

Platform vs. Add-On: The Multiple for a Medical Practice Varies by Buyer

The same practice can carry two very different valuations depending on whether a private equity firm is buying it as a platform or folding it into an existing one. Understanding which side of that line a practice sits on is often the difference between a 5x outcome and a 12x outcome.

A platform acquisition is a PE firm's initial entry into a specialty. The firm is paying for more than the cash flow: it is buying a management team, a brand, an operating system, and the infrastructure to onboard subsequent acquisitions. Platform targets usually have $5M to $15M+ of EBITDA, a CEO or managing physician capable of leading regional growth, defensible margins, and ideally some ancillary revenue. Platform multiples in 2026 run 10x-20x EBITDA depending on specialty, per FOCUS Investment Banking data.

An add-on acquisition is a smaller practice folded into an existing platform. The buyer already has the management, billing infrastructure, vendor contracts, and compliance systems; what it needs is more provider capacity and geographic density. Add-on multiples run 3-5 turns lower than platforms in the same specialty, typically 4x-10x EBITDA. The classic PE play is the multiple arbitrage between the two: buy add-ons at 6x, integrate them into a platform valued at 11x, then re-exit the larger platform at 12x-14x five to seven years later.

For an owner deciding which side of the platform/add-on line their practice sits on, two questions usually settle it. First, is EBITDA above the $5M threshold that platform buyers underwrite? Second, is the management team independent of the founding physician, with a successor or operating leader who can run the business through a transition? An answer of "no" to either typically signals an add-on outcome, which is not a bad outcome at all, just a different one with a different multiple attached.

Owners with a practice that sits near the platform line, where the multiple gap is largest, get the most value from advisor-led process design. Iconic has guided more than 200 business owners through transactions where buyer-type framing materially changed the final pricing.

What Drives Multiples Up: Scale, Payer Mix, and Ancillaries

Within a given specialty and buyer band, three operational variables explain most of the variance in medical practice valuation multiples.

Scale. Practices with EBITDA above $5M typically command 2-4 multiple points higher than smaller add-on candidates, per FOCUS Investment Banking's 2026 data. The math behind the premium: larger practices have lower execution risk, dedicated finance and operations leadership, more durable referral relationships, and a deeper bench of providers so revenue does not collapse if one physician leaves. They can also absorb the diligence and integration costs that crush smaller deals.

Payer mix. Practices with commercial payer mix above 70% of revenue see valuations 40-60% higher than practices dependent on Medicare and Medicaid, per FOCUS Investment Banking and ClearlyAcquired analysis. The driver is straightforward: commercial reimbursement runs roughly 89% above Medicare for comparable services, so commercial-heavy revenue produces materially higher EBITDA per encounter. Practices in markets with strong commercial networks, low Medicaid penetration, and solid in-network status with major payers carry a structural advantage in the multiple they can command. Government-payer-heavy practices are not unmarketable, but the buyer universe narrows and pricing reflects the reimbursement reality.

Owned ancillary services. Ambulatory surgery centers, imaging, cath labs, infusion, pathology, and other owned ancillaries add 1-3 turns to the EBITDA multiple per FOCUS Investment Banking. The premium reflects three things at once: ancillary EBITDA carries higher margins than professional services, the revenue diversifies the practice away from physician-hour-driven income, and the underlying assets create barriers to entry for competing groups. A gastroenterology practice with an embedded endoscopy center is not just worth more in absolute terms - its multiple is higher per dollar of EBITDA.

A fourth driver sits below these three in headline impact but matters in diligence: provider productivity and retention. Buyers underwrite physician compensation against MGMA productivity benchmarks. Practices where physicians are paid above market without commensurate productivity, or where senior providers are nearing retirement without a succession plan, see normalized EBITDA fall and the multiple compress as buyers price succession risk. The same dynamic shows up in practices over-reliant on a single referring source: concentration above 20% from any one referrer typically warrants a discount or an earn-out structure. For broader perspective on the strategic groundwork that compounds these drivers, our list of 10 must-read business books for selling covers frameworks worth reviewing before going to market.

Putting These Medical Practice Valuation Multiples Into Practice

The numbers in this article are not a chart to memorize. Medical practice valuation multiples are a band determined by the intersection of specialty, scale, payer mix, ancillary mix, and buyer type. A solo dermatology practice and a 25-physician dermatology platform will both call themselves dermatology practices, and one will sell at 2.5x SDE while the other clears 12x EBITDA. Everything above explains why.

For an owner thinking about a transition in the next two to five years, the productive work is not memorizing the ranges. It is honestly assessing where the practice currently scores against the drivers buyers actually pay for, and which of those drivers can realistically be improved in the time available before going to market. Sometimes the right answer is to sell into the current platform-multiple environment; sometimes the right answer is to spend 18 months building scale, restructuring payer mix, or layering in an ancillary and capture the higher multiple on the back end.

Iconic has guided more than 200 business owners through that decision and the process that follows. To understand where your practice would price today and what it would take to move it into the next valuation band, start with a complimentary business valuation.